DISCLOSURE: as of 6/26 I have no open position in RO
Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment.
Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position.
Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case.
Summary: Roche looks like a quality company to potentially take some profits and diversify from my SIGA position. However, for now it will stay on the watch list. I will be looking at USDCHF as well as the valuation metrics I mentioned above.
Here on my macroeconomic and current research shortlist watchlists:
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.